Alka-seltzer Gold Tablet, Effervescent
NDC Package 0280-4100-63

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Alka-seltzer Gold tablets is uses for the relief of ● heartburn ● acid indigestion ● sour stomach. This formulation utilizes a tablet, effervescent delivery system. Marketed by Bayer Healthcare Llc., this product is identified by NDC 0280-4100 and is authorized under FDA application M001.

Identification & Billing

NDC Package Code
0280-4100-63
Package Description
18 POUCH in 1 CARTON / 2 TABLET, EFFERVESCENT in 1 POUCH
Product Code
11-Digit Billing Format
00280410063
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
18 EA
RxNorm Crosswalk
  • RxCUI: 1536474 - citric acid 1000 MG / potassium bicarbonate 344 MG / sodium bicarbonate 1050 MG Effervescent Oral Tablet
  • RxCUI: 1536474 - Citric Acid 1000 MG / K+ bicarbonate 344 MG / NaHCO3 1050 MG Effervescent Oral Tablet
  • RxCUI: 1536474 - Citric Acid 1000 MG / Pot bicarbonate 344 MG / NaHCO3 1050 MG Effervescent Oral Tablet

Clinical Specifications

Proprietary Name
Alka-seltzer Gold
Non-Proprietary Name
Alka-seltzer Gold
Substance Name
Citric Acid Monohydrate; Potassium Bicarbonate; Sodium Bicarbonate
Dosage Form
Tablet, Effervescent - A solid dosage form containing mixtures of acids (e.g., citric acid, tartaric acid) and sodium bicarbonate, which release carbon dioxide when dissolved in water; it is intended to be dissolved or dispersed in water before administration.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Uses for the relief of ● heartburn ● acid indigestion ● sour stomach

Regulatory & Marketing

Labeler Name
Bayer Healthcare Llc.
Product Type
Human Otc Drug
FDA Application #
M001
Marketing Category
OTC MONOGRAPH DRUG -
Start Marketing Date
11-19-2014
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0280-4100-63 identifies a specific commercial package of 18 pouch in 1 carton / 2 tablet, effervescent in 1 pouch of Alka-seltzer Gold, a human over the counter drug labeled by Bayer Healthcare Llc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 18 billable units per package. This tablet, effervescent is formulated for oral use and contains citric acid monohydrate; potassium bicarbonate; sodium bicarbonate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Llc. on November 19, 2014. The current certification is valid through December 31, 2026.

How is this Bayer Healthcare Llc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00280410063. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 18 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0280-4100-63
11-Digit CMS (5-4-2)
00280-4100-63

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.